For the quarter ended March 2026, GoodRx Holdings, Inc. (GDRX) reported revenue of $194.01 million, down 4.4% over the same period last year. EPS came in at $0.07, compared to $0.09 in the year-ago quarter.
The reported revenue represents a surprise of +7.73% over the Zacks Consensus Estimate of $180.09 million. With the consensus EPS estimate being $0.07, the EPS surprise was -5.41%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts. Subscription plans: 717 versus the two-analyst average estimate of 679. Revenue- Prescription transactions: $113.69 million versus $114.73 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -23.7% change. Revenue- Other: $3.69 million versus the three-analyst average estimate of $3.99 million. The reported number represents a year-over-year change of -15.8%. Revenue- Pharma direct: $52.23 million versus the three-analyst average estimate of $40.07 million. The reported number represents a year-over-year change of +82.3%. Revenue- Subscription: $24.39 million versus $21.68 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change.View all Key Company Metrics for GoodRx here>>>
Shares of GoodRx have returned +24.9% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GoodRx Holdings, Inc. (GDRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).